AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06521788 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Routine breast ultrasound
Description: Routine breast ultrasound conducted by primary care physicians
Study NCT03027973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UPA
Description: Experimental drug
Study NCT03027973 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TEA
Description: Active comparator
Study NCT03027973 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for UPA)
Description: Sugar pill manufactured to mimic UPA 5 mg
Study NCT03027973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for TEA)
Description: Sugar pill manufactured to mimic TEA 500mg
Study NCT04141137 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TricValve® System
Description: The TricValve® Delivery System (catheter) with already pre-mounted biological heart valve is inserted from the femoral vein to access the inferior vena cava (IVC) and superior vena cava (SVC) of the heart under fluoroscopy guidance. The appropriately sized TricValve® is released at the implantation site and positions itself as per the anatomy - self expanding frame.
Study NCT03673839 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Animal Proteins (crossover)
Description: Animal proteins mixed with water and consumed as a beverage once by the subject in a 4x4 Williams square crossover design
Study NCT03673839 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Animal Proteins (crossover)
Description: Animal proteins mixed with water and consumed as a beverage once by the subject in a 4x4 Williams square crossover design
Study NCT03673839 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plant-based protein blends type 1 (crossover)
Description: Plant-based protein blends mixed with water and consumed as a beverage once by the subject in a 4x4 Williams square crossover design
Study NCT03673839 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plant-based protein blends type 1 (crossover)
Description: Plant-based protein blends mixed with water and consumed as a beverage once by the subject in a 4x4 Williams square crossover design
Study NCT03673839 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plant-based protein blends type 2 (crossover)
Description: Plant-based protein blends mixed with water and consumed as a beverage once by the subject in a 4x4 Williams square crossover design
Study NCT03673839 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plant-based protein blends type 2 (crossover)
Description: Plant-based protein blends mixed with water and consumed as a beverage once by the subject in a 4x4 Williams square crossover design
Study NCT03673839 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plant-based protein blends type 3 (crossover)
Description: Plant-based protein blends mixed with water and consumed as a beverage once by the subject in a 4x4 Williams square crossover design
Study NCT03673839 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plant-based protein blends type 3 (crossover)
Description: Plant-based protein blends mixed with water and consumed as a beverage once by the subject in a 4x4 Williams square crossover design
Study NCT03419806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infudopa i.v.
Description: Infudopa i.v. infusion will be given through an indwelling catheter placed in the arm. Infudopa i.v. will be delivered in 75% of the subject's individual pre-study dosing of Duodopa.~From patient 6 and onwards:~Infudopa IntraV, at 81% of the subject's individual pre-study daily Duodopa dose, will be delivered over a 16-h period and administered as a continuous fixed infusion rate preceded by a morning bolus dose. The i.v. morning bolus is 110% of the hourly continuous dose delivered at the rate of 60 ml/h (mixed volume rate Infudopa Active + Infudopa Buffer IntraV). The morning dose will not exceed 24 mL, corresponding to 240 mg levodopa. The maximum daily dose levodopa during i.v. administration is not allowed to exceed 3240mg (equal to 81% of the maximum allowed daily dosage for Duodopa that is 4000 mg).
Study NCT03419806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infudopa s.c.
Description: A suitable infusion needle will be placed laterally on the abdomen for the s.c. infusion of Infudopa. Infudopa s.c. will be delivered in the same dosage as the subject's individual pre-study dosing of Duodopa, as a morning rapid s.c. constant rate administration followed by continuous s.c. infusion up to 16 h.~From patient 6 and onwards:~Two infusion needles will be placed on the abdomen for the s.c. infusion of Infudopa SubC in 86% of the the subject's individual pre-study daily Duodopa dose. The intervention is given as a continuous fixed infusion rate for 16h preceded by a morning bolus dose. The s.c. morning bolus is 155% of the hourly continuous dose delivered at the rate of 80 ml/h (mixed volume rate Infudopa Active + Infudopa Buffer SubC). The morning dose will not exceed 30 mL. The maximum daily dose levodopa during s.c. administration is not allowed to exceed 3440mg (equal to 86% of the maximum allowed daily dosage for Duodopa that is 4000 mg).
Study NCT02824991 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: detection of local twitch response intensities during dry needling
Study NCT01833221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: injection of 1% lidocaine, 2mL for facial nerve block
Description: injection with a fine needle of 2mL lidocaine in close contact of the facial nerve trunk
Study NCT01566474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: Omeprazole 40 mg/day alone. Patients will take the capsule once in the morning before breakfast. This is the standard therapy for patients suffering from Barrett's esophagus.
Study NCT01566474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Omeprazole 40 mg/day + Circadin 6 mg/12 hours. Patients will take the Omeprazole capsule once in the morning before breakfast together with 3 tables of 2 mgs of Circadin (melatonin). In the evening, before dinner, patients will take 3 tablets of 2 mg of Circadin.
Study NCT00393770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-acetylcarnitine
Description: 250-500 mg/kg/die.
Study NCT04114526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy
Description: CHAs meet with all interested residents to discuss taking steps towards quitting. The CHAs follow a four step program with all participant 1) get to know the resident and their smoking, 2) Assess what the resident is ready to do to take steps towards quitting, 3) discuss using nicotine replacement therapy (NRT) in the form of patches, gum or lozenges, 4) set one goal for taking steps towards quitting. CHAs will attempt to follow up with participants after the initial encounter. There is no limit on the number of times the CHA may talk with the participants. Some follow interactions will be brief encounters in the neighborhood, while others will be at scheduled. All contacts with each participant will be tracked.~We will provide up to 6 weeks of NRT patches, gum and lozenges to participants who are interested in using NRT to help them quit.
Study NCT04518319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 polyunsaturated fatty acids
Description: Omega-3 polyunsaturated fatty acids will be taken 1200mg per day plus on olanzapine.
Study NCT04518319 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Xbox aerobic exercise
Description: Patients will do Xbox aerobic exercise 30min per day plus on olanzapine.
Study NCT04518319 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation,tDCS
Description: Patients will receive tDCS at 2mA, 20 min for 5 session per week plus on olanzapine.
Study NCT04518319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Patients will take only olanzapine pills.
Study NCT04280393 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy procedure with endocuff
Description: Colonoscopy procedure with the use of ENDOCUFF VISION
Study NCT04280393 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Colonoscopy procedure with endocuff
Description: Colonoscopy procedure with the use of ENDOCUFF VISION
Study NCT02129530 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Social Mobilization program
Study NCT04259801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0480-0389
Description: Part 1: A single dose of NNC0480-0389, dose increased in each cohort. Part 2: Weekly doses (for 4 weeks) of NNC0480-0389, dose increased in each cohort.
Study NCT04259801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Part 1: Single dose of semaglutide (0.5 mg). Part 2: Weekly doses of semaglutide alone for 8 weeks (2 x 0.25 mg, 2 x 0.5 mg and 4 x 1 mg) followed by weekly fixed doses of 1 mg semaglutide for 4 weeks.
Study NCT04259801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: Part 1: Single dose of semaglutide (0.5 mg). Part 2: Weekly doses of semaglutide alone for 8 weeks (2 x 0.25 mg, 2 x 0.5 mg and 4 x 1 mg) followed by weekly fixed doses of 1 mg semaglutide for 4 weeks.
Study NCT04259801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (NNC0480-0389)
Description: Placebo for NNC0480-0389. Part 1: A single dose of placebo (NNC0480-0389), dose increased in each cohort. Part 2: Weekly doses (for 4 weeks) of placebo A, dose increased in each cohort.
Study NCT04259801 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (NNC0480-0389)
Description: Placebo for NNC0480-0389. Part 1: A single dose of placebo (NNC0480-0389), dose increased in each cohort. Part 2: Weekly doses (for 4 weeks) of placebo A, dose increased in each cohort.
Study NCT04259801 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (semaglutide)
Description: Part 1: Single dose of placebo (semaglutide) (0.5 mg). Part 2: Weekly doses of placebo (semaglutide) alone for 8 weeks (2 x 0.25 mg, 2 x 0.5 mg and 4 x 1 mg) followed by weekly fixed doses of 1 mg semaglutide for 4 weeks.
Study NCT04259801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (semaglutide)
Description: Part 1: Single dose of placebo (semaglutide) (0.5 mg). Part 2: Weekly doses of placebo (semaglutide) alone for 8 weeks (2 x 0.25 mg, 2 x 0.5 mg and 4 x 1 mg) followed by weekly fixed doses of 1 mg semaglutide for 4 weeks.
Study NCT04347031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mefloquine
Description: 1st day: 750 mg of mefloquine per day, inside, in tablets of 250 mg 3 times a day - 1 tablet every 8 hours.~* Day 2: 500 mg of mefloquine, inside, in tablets of 250 mg 2 times a day - 1 tablet every 12 hours.~* 3rd - 7th day: 250 mg of mefloquine, inside, in tablets of 250 mg 1 time a day at the same time.
Study NCT04347031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 1. st day: 800 mg of hydroxychloroquine per day, inside, in 200 mg tablets, 2 tablets 2 times a day;~2. nd - 7th day: 400 mg of hydroxychloroquine per day, inside, in tablets of 200 mg, 1 tablet 2 times a day.
Study NCT04347031 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Mefloquine + azithromycin + / - tocilizumab
Description: 1st day: 750 mg of mefloquine per day, inside, in tablets of 250 mg 3 times a day - 1 tablet every 8 hours.~* Day 2: 500 mg of mefloquine, inside, in tablets of 250 mg 2 times a day - 1 tablet every 12 hours.~* 3rd - 7th day: 250 mg of mefloquine, inside, in tablets of 250 mg 1 time a day at the same time.
Study NCT04347031 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine + azithromycin + / - tocilizumab
Description: 1. st day: 800 mg of hydroxychloroquine per day, inside, in 200 mg tablets, 2 tablets 2 times a day;~2. nd - 7th day: 400 mg of hydroxychloroquine per day, inside, in tablets of 200 mg, 1 tablet 2 times a day.
Study NCT02690584 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metacognitive therapy
Study NCT03371238 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Floorball
Description: The subjects in this group are set to play floorball three times pr. week for 39 weeks.
Study NCT02100241 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Active stretching
Description: The participants performed three specific exercises of static active stretching of the hamstring muscles, maintaining the maximum tightness that was tolerable without pain for 15 seconds. Each exercise were performed twice, with a total of six repetitions.
Study NCT03539731 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorine F 18 DASA-23
Description: Given IV
Study NCT03539731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorine F 18 DASA-23
Description: Given IV
Study NCT03539731 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET scan
Study NCT03539731 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan
Study NCT02670200 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavior therapy
Description: treatment technique to help people to overcome psychological distress and mental diseases
Study NCT02670200 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive behavior therapy
Description: treatment technique to help people to overcome psychological distress and mental diseases
Study NCT03149965 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: transperineal ultrasound
Description: transperineal ultrasound was used by placing a vaginal ultrasound probe towards the vaginal distal wall pointing to the anus, measuring the anovaginal distance.
Study NCT03149965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transperineal ultrasound
Description: transperineal ultrasound was used by placing a vaginal ultrasound probe towards the vaginal distal wall pointing to the anus, measuring the anovaginal distance.
Study NCT04252508 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Animated film
Description: An animated film depicts the child and the caregivers in the form of avatars and retraces his journey from his room to the transfer area, then to the the operating room and finally to the post-intervention ward.
Study NCT02434796 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Male Peer Groups
Description: In Intervention Arm 1, male partners participate in male peer group workshops on gender norms, IPV and HIV prevention. Men's peer groups address gender inequality and transformation of gender power relations, positive masculinities and accountability of men in the perpetration of violence against women. This intervention aims to improve knowledge and attitudes among men about the harms of IPV on women, men and children; the confidence to internalize positive masculine ideals and to challenge gender stereotypes; and the ability to formulate positive outcome expectations regarding IPV and healthy relationships with their spouses and communities. Male peer group workshops will be conducted as a series of four workshops for a total of 24 hours spread out over a 5-month period.
Study NCT02434796 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Male Peer Groups and Community Dialogues
Description: Men participate in male peer group workshops as in Intervention Arm 1. In addition, village level community leaders engage in community mobilization/sensitization activities that include women members of savings groups and their male partners who participate male peer groups. Community dialogues focus on gender norms, IPV and HIV prevention. First, a one-day workshop for community leaders on topics similar to those raised in male peer group sessions. Second, trained community leaders facilitate community dialogues on IPV, HIV prevention, and gender norms with savings groups members and their male partners who participate in male peer groups. Each workshop will be a day-long event.
Study NCT03506854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 681257
Description: Xmg dose administered as a subcutaneous injection
Study NCT03576430 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active stress handling
Description: biofeed back stress handling
Study NCT00520494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vivaglobin
Description: Human normal immunoglobulin G (IgG) for subcutaneous (SC) use.
Study NCT02073305 — intervention group
Intervention type: OTHER
Intervention: No Sleep Apnea
Description: No intervention
Study NCT02073305 — intervention group
Intervention type: OTHER
Intervention: Sleep Apnea - untreated
Description: No intervention
Study NCT02073305 — intervention group
Intervention type: DEVICE
Intervention: Sleep Apnea - treated
Description: Sleep Apnea treatment by positive pression ventilation (CPAP/BIPAP) or sleep apnea oral appliance
Study NCT04641754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WX-0593 Tablets
Description: tablets, 60 mg→180mg, quaque die（QD）
Study NCT02643394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Acetaminophen
Description: 1000mg oral acetaminophen + 400mg oral celecoxib given within one hour of incision
Study NCT02643394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous acetaminophen
Description: 400mg oral celecoxib given within one hour of incision + 1000mg IV acetaminophen within one hour prior to anesthetic emergence.
Study NCT03250013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADHD medications
Study NCT03471182 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychiatric and Cognitive Testing
Description: Interviews, questionnaires, and computer testing.
Study NCT03471182 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cocaine Self-adminstration
Description: The intervention will include a training and safety session that consists of physician/nurse-administered cocaine followed by a self-regulated cocaine administration period under carefully controlled and closely monitored conditions.
Study NCT03471182 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: PET scans will be performed on a High Resolution Research Tomograph (HRRT), the highest resolution human brain scanner available. Antecubital venous catheters will be used for IV administration of the radiotracer and for venous blood sampling. A radial artery catheter may also be inserted by an experienced physician before the PET scan. At the beginning of each scan, the participants's head will be immobilized and a 6-minute transmission scan, using an orbiting 137Cs point-source, is obtained and used for attenuation correction. PET scans will be acquired using bolus or bolus plus constant infusion administration of \[18F\]FPEB.
Study NCT03471182 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Structural and functional MRI data will be acquired using a Siemens Trio TIM 3.0T system at the Yale Magnetic Resonance Research Center. High-resolution structural MRI data will be acquired to facilitate analysis of PET data and may be used in additional analysis of tissue volume and brain structure. Resting-state and task-based functional MRI data will be acquired using state-of-the-art multiband echo-planar imaging (EPI) gradient-echo sequences. Diffusion-weighted MRI data will also be acquired using multiband imaging sequences to investigate anatomical connectivity.
Study NCT02952937 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GLA5PR GLARS-NF3 tablet 300mg
Description: A new formulation(3rd.) of Pregabalin CR tablet
Study NCT02952937 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GLA5PR GLARS-NF1 tablet 300mg
Description: A new formulation(1st.) of Pregabalin CR tablet
Study NCT01408056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol 0.5% Gel Forming Solution (GFS)
Description: Dose-based escalation schedule for topical application:~4-8 kg: Day 0-7: 1 drop every other day; Day 7-14: 1 drop daily; Day 14 - Day 60: 1 drop twice per day~8-12 kg: Day 07: 1 drop daily; Day 7-14: 1 drop twice per day; Day 14 - Day 60: 2 drops twice per day
Study NCT01408056 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mupirocin 2% Ointment
Description: Topical application twice per day for 60 days
Study NCT03174925 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Siemens Acuson S3000 ultrasound system
Description: Shear Wave Elastography
Study NCT01343043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be used as lymphodepleting chemotherapy.
Study NCT01343043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be used as lymphodepleting chemotherapy.
Study NCT00605618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-777607
Description: Suspension/Tablet, Oral, Dose escalation to an MTD from a starting dose of 10 mg, once daily, until disease progression/subject discontinuation
Study NCT01099618 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: The study subject will receive metformin (MET) 1000 mg tablet once a day as long as the patient maintains near-normoglycemic remission (BG \< 130mg/dL and A1c \<7%) during the 3-year follow-up period.
Study NCT01099618 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The study subject will receive a placebo tablet once a day as long as the patient maintains near-normoglycemic remission (BG \< 130mg/dL and A1c \<7%) during the 3-year follow-up period.